Literature DB >> 35247916

Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion.

Allison R Baker1, Christos Miliotis1, Julia Ramírez-Moya1,2,3, Talia Marc1, Ioannis S Vlachos1,4, Pilar Santisteban2,3, Frank J Slack1.   

Abstract

ADARs catalyze adenosine-to-inosine (A-to-I) editing of double-stranded RNA and regulate global gene expression output through interactions with RNA and other proteins. ADARs play important roles in development and disease, and previous work has shown that ADAR1 is oncogenic in a growing list of cancer types. Here we show that ADAR1 is a critical gene for triple-negative breast cancer cells, as ADAR1 loss results in reduced growth (viability and cell cycle progression), invasion, and mammosphere formation. Whole transcriptome sequencing analyses demonstrate that ADAR1 regulates both coding and noncoding targets by altering gene expression level, A-to-I editing, and splicing. We determine that a recoding edit in filamin B (FLNB chr3:58156064) reduces the tumor suppressive activities of the protein to promote growth and invasion. We also show that several tumor suppressor miRNAs are upregulated upon ADAR1 loss and suppress cell-cycle progression and invasion. This work describes several novel mechanisms of ADAR1-mediated oncogenesis in triple-negative breast cancer, providing support to strategies targeting ADAR1 in this aggressive cancer type that has few treatment options. IMPLICATIONS: Targeting ADAR1 and thus downstream FLNB editing and miRNA regulation represents a possible novel therapeutic strategy in triple-negative breast cancer. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35247916      PMCID: PMC9177724          DOI: 10.1158/1541-7786.MCR-21-0604

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  50 in total

1.  ADAR1 Transcriptome editing promotes breast cancer progression through the regulation of cell cycle and DNA damage response.

Authors:  Eduardo A Sagredo; Alfredo I Sagredo; Alejandro Blanco; Pamela Rojas De Santiago; Solange Rivas; Rodrigo Assar; Paola Pérez; Katherine Marcelain; Ricardo Armisén
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-04-08       Impact factor: 4.739

2.  Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.

Authors:  Jeffrey J Ishizuka; Robert T Manguso; Collins K Cheruiyot; Kevin Bi; Arpit Panda; Arvin Iracheta-Vellve; Brian C Miller; Peter P Du; Kathleen B Yates; Juan Dubrot; Ilana Buchumenski; Dawn E Comstock; Flavian D Brown; Austin Ayer; Ian C Kohnle; Hans W Pope; Margaret D Zimmer; Debattama R Sen; Sarah K Lane-Reticker; Emily J Robitschek; Gabriel K Griffin; Natalie B Collins; Adrienne H Long; John G Doench; David Kozono; Erez Y Levanon; W Nicholas Haining
Journal:  Nature       Date:  2018-12-17       Impact factor: 49.962

3.  Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.

Authors:  Leilei Chen; Yan Li; Chi Ho Lin; Tim Hon Man Chan; Raymond Kwok Kei Chow; Yangyang Song; Ming Liu; Yun-Fei Yuan; Li Fu; Kar Lok Kong; Lihua Qi; Yan Li; Na Zhang; Amy Hin Yan Tong; Dora Lai-Wan Kwong; Kwan Man; Chung Mau Lo; Si Lok; Daniel G Tenen; Xin-Yuan Guan
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

Review 4.  A-to-I editing of coding and non-coding RNAs by ADARs.

Authors:  Kazuko Nishikura
Journal:  Nat Rev Mol Cell Biol       Date:  2015-12-09       Impact factor: 94.444

5.  The miR-23a∼27a∼24-2 microRNA Cluster Promotes Inflammatory Polarization of Macrophages.

Authors:  Austin Boucher; Nathan Klopfenstein; William Morgan Hallas; Jennifer Skibbe; Andrew Appert; Seok Hee Jang; Kirthi Pulakanti; Sridhar Rao; Karen D Cowden Dahl; Richard Dahl
Journal:  J Immunol       Date:  2020-12-16       Impact factor: 5.422

6.  Differential Binding of Three Major Human ADAR Isoforms to Coding and Long Non-Coding Transcripts.

Authors:  Josephine Galipon; Rintaro Ishii; Yutaka Suzuki; Masaru Tomita; Kumiko Ui-Tei
Journal:  Genes (Basel)       Date:  2017-02-11       Impact factor: 4.096

Review 7.  The TNF Paradox in Cancer Progression and Immunotherapy.

Authors:  Anne Montfort; Céline Colacios; Thierry Levade; Nathalie Andrieu-Abadie; Nicolas Meyer; Bruno Ségui
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

8.  Coordinated targeting of the EGFR signaling axis by microRNA-27a*.

Authors:  Xiaoli Wu; Mihir K Bhayani; Cristina T Dodge; Milena S Nicoloso; Yunyun Chen; Xiaofeng Yan; Makoto Adachi; Ligy Thomas; Chad E Galer; Tilahun Jiffar; Curtis R Pickering; Michael E Kupferman; Jeffrey N Myers; George A Calin; Stephen Y Lai
Journal:  Oncotarget       Date:  2013-09

9.  Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Authors:  Debora Fumagalli; David Gacquer; Françoise Rothé; Anne Lefort; Frederick Libert; David Brown; Naima Kheddoumi; Adam Shlien; Tomasz Konopka; Roberto Salgado; Denis Larsimont; Kornelia Polyak; Karen Willard-Gallo; Christine Desmedt; Martine Piccart; Marc Abramowicz; Peter J Campbell; Christos Sotiriou; Vincent Detours
Journal:  Cell Rep       Date:  2015-10-01       Impact factor: 9.423

10.  RNA editing of Filamin A pre-mRNA regulates vascular contraction and diastolic blood pressure.

Authors:  Mamta Jain; Tomer D Mann; Maja Stulić; Shailaja P Rao; Andrijana Kirsch; Dieter Pullirsch; Xué Strobl; Claus Rath; Lukas Reissig; Kristin Moreth; Tanja Klein-Rodewald; Raffi Bekeredjian; Valerie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Eleonore Pablik; Laura Cimatti; David Martin; Jelena Zinnanti; Wolfgang F Graier; Maria Sibilia; Saša Frank; Erez Y Levanon; Michael F Jantsch
Journal:  EMBO J       Date:  2018-08-07       Impact factor: 11.598

View more
  2 in total

Review 1.  ADAR1 and its implications in cancer development and treatment.

Authors:  Allison R Baker; Frank J Slack
Journal:  Trends Genet       Date:  2022-04-19       Impact factor: 11.821

2.  IFN-I inducible miR-3614-5p targets ADAR1 isoforms and fine tunes innate immune activation.

Authors:  Françoise Vuillier; Zhi Li; Iain Black; Melania Cruciani; Erminia Rubino; Frédérique Michel; Sandra Pellegrini
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.